The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

When Biogen announced the deal, the company said it expected a “significant portion” of Apellis staffers would stay on board. (No-Mad/iStock/Getty Images Plus) Biogen isn’t wasting any time ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since, founder and CEO ...

During her presentation, Moderna’s Das said the company proposed a “modified regulatory framework” during the FDA meeting.

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring former Roche executive Paulo ...

The FDA has sent an End of Enforcement notice to consumer wearable device company Whoop, putting a formal end to the agency’s ...

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...